INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Impact · against what's priced in

Larimar Therapeutics faces significant downward pressure due to a severe safety signal (anaphylaxis in 23% of patients) and subsequent securities fraud investigations. While the company has submitted a rolling BLA, the clinical risks and legal headwinds outweigh the regulatory progress.

LRMR−0.80

No priced-in read yet